Drug therapy safety: methotrexate-associated medication errors

Clicks: 10
ID: 321234
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #28 of 93 articles by views in turkish journal of public health

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Aim Drug therapy safety aims at ensuring optimal medication while reducing errors and preventing avoidable patient risks. The transition from outpatient to inpatient care is especially vulnerable to medication-related problems (MRPs), including those related to transferring outpatient medication orders into electronic health records. This phase is particularly vulnerable for drugs with dose-dependent pharmacological effects, such as methotrexate (MTX). Methods Within the framework of INTERPOLAR (INTERventional POLypharmacy – drug interAction – Risks), clinical pharmacists regularly perform medication analyses as are routinely carried out across multiple departments of the Jena University Hospital (UKJ). Identified problems are addressed through interdisciplinary collaboration. The analyses rely on essential patient information, including medical history, diagnoses, clinical findings, and laboratory results, as well as current medications. Results Medication analyses identified five cases within 5 months with MRPs related to MTX across departments during hospitalization at UKJ. Conclusion Although MTX-related MRPs are well known and despite established risk-minimization measures, failures still occur. The present case series highlights the need for regular active, interdisciplinary safety strategies. These should go beyond predominantly passive informative measures. Cooperation between treating physicians and clinical pharmacists should be strengthened and made standard practice, especially during hospitalization of patients with complex or potentially dangerous regimens. Drugs with complex or variable dosing schemes increase risk of MRPs. Early interdisciplinary collaboration among clinical pharmacists, physicians, and nurses helps to identify and prevent potential MRPs.
Reference Key
openalex_W7169043781 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Franz F. Janke, Christine Keßler, Michael Hartmann, Ross J. Baldessarini, Katrin Farker
Journal turkish journal of public health
Year 2026
DOI
10.1007/s10389-026-02857-2
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.